EU/3/12/987

About

On 26 April 2012, orphan designation (EU/3/12/987) was granted by the European Commission to JJGConsultancy Ltd, United Kingdom, for (E)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzyl-sulfone sodium salt for the treatment of myelodysplastic syndromes.

The sponsorship was transferred to Onconova Europe GmbH, Germany, in February 2014.

The sponsor’s address was updated in March 2021.

Key facts

Active substance
(E)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzyl-sulfone sodium salt
Disease / condition
Treatment of myelodysplastic syndromes
Date of first decision
26/04/2012
Outcome
Positive
EU designation number
EU/3/12/987

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Onconova Europe GmbH
Kaflerstrasse 6
Pasing-Obermenzing
81241 Munich
Germany
Tel.: 1 267 759 3680
E-mail: info@onconova.us

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating